摘要
钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂是一种新型的口服降糖药,越来越多的临床研究显示SGLT2抑制剂可以改善糖尿病或非糖尿病患者的心血管预后,显示出SGLT2抑制剂的多效性。但SGLT2抑制剂在急性心肌梗死中的作用尚不明确,本文就SGLT2抑制剂在急性心肌梗死动物实验和临床研究作一综述。
The sodium glucose cotransporter 2(SGLT2)inhibitor is a new type of oral hypoglycemic drug.An increasing number of clinical studies show that SGLT2 inhibitors could improve the cardiovascular prognosis of diabetes or non-diabetes patients,showing the pleiotropic effect of SGLT2 inhibitors.However,the role of SGLT2 inhibitors in acute myocardial infarction remains unclear.This article reviews animal experiments and clinical studies of SGLT2 inhibitors in acute myocardial infarction.
作者
陈诚
张钲
彭瑜
牛小伟
何世林
窦文朝
CHEN Cheng;ZHANG Zheng;PENG Yu;NIU Xiaowei;HE Shilin;DOU Wenchao(the First School of Clinical Medicine,Lanzhou University,Lanzhou,730099,China;Heart Center,the First Hospital of Lanzhou University;Key Laboratory of Cardiovascular Diseases of Gansu Province)
出处
《临床心血管病杂志》
CAS
2024年第5期411-415,共5页
Journal of Clinical Cardiology
基金
国家自然科学基金项目(No:82000277、82060807)。
